Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Head and neck, Oncology, Head and neck cancer, Head and neck squamous-cell carcinoma, and Internal medicine.
PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC
1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Tracheostomy during <scp>SARS‐CoV</scp>‐2 pandemic: Recommendations from the New York Head and Neck Society
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Exhaled breath analysis in the diagnosis of head and neck cancer
The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond
Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials
Adenoid cystic carcinoma of the head and neck – An update
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review
Cervical lymph node metastases from remote primary tumor sites
The role of systemic therapy in the management of sinonasal cancer: A critical review
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Salivary mucoepidermoid carcinoma revisited
A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
Prevention of head and neck squamous cell carcinoma: Removing the “chemo” from “chemoprevention”
Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate
Recent trends in the management of minor salivary gland carcinoma
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma
Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group